These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4540590)

  • 1. Cell-mediated immunity in vitro against syngeneic mouse plasma tumour cells.
    Wagner H; Röllinghoff M
    Nat New Biol; 1973 Jan; 241(106):53-4. PubMed ID: 4540590
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.
    Wagner H; Röllinghoff M
    J Exp Med; 1973 Jul; 138(1):1-15. PubMed ID: 4541509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcellular mouse alloantigens: cytotoxic immune responses and specific blocking in vitro.
    Wagner H; Boyle W
    Nat New Biol; 1972 Nov; 240(98):92-4. PubMed ID: 4539049
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.
    Röllinghoff M; Rouse BT; Warner NL
    J Natl Cancer Inst; 1973 Jan; 50(1):159-72. PubMed ID: 4571237
    [No Abstract]   [Full Text] [Related]  

  • 6. Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes.
    Röllinghoff M; Wagner H
    J Natl Cancer Inst; 1973 Oct; 51(4):1317-8. PubMed ID: 4745860
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL.
    Kaneko Y; Natsuume-Sakai S; Migita S
    J Immunol; 1978 Aug; 121(2):427-37. PubMed ID: 79604
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppressive versus augmenting effect of the same pretreatment regimen in two murine tumor systems with distinct effector mechanisms.
    Fufiwara H; Hamaoka T; Kitagawa M
    Gan; 1978 Dec; 69(6):793-803. PubMed ID: 312225
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes.
    Rouse BT; Wagner H; Harris AW
    J Immunol; 1972 May; 108(5):1353-61. PubMed ID: 4623947
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro induction of tumor-specific immunity. III. Lack of requirement for H-2 compatibility in lysis of tumor targets by T cells activated in vitro to oncofetal and plasmacytoma antigens.
    Burton RC; Chism SE; Warner NL
    J Immunol; 1977 Mar; 118(3):971-80. PubMed ID: 300394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.
    Fujiwara H; Hamaoka T; Shearer GM; Yamamoto H; Terry WD
    J Immunol; 1980 Feb; 124(2):863-9. PubMed ID: 6965392
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cellular immunity in mouse plasmocytomas].
    Lespinats G; Poupon MF
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):755-65. PubMed ID: 5050876
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice.
    Teller MN; Faanes RB
    Cancer Res; 1980 Aug; 40(8 Pt 1):2790-5. PubMed ID: 6966969
    [No Abstract]   [Full Text] [Related]  

  • 15. H-2 region product as determinant in immune cytolysis of syngeneic tumour cells by anti-MSV T lymphocytes.
    Gomard E; Duprez V; Henin Y; Levy JP
    Nature; 1976 Apr; 260(5553):707-9. PubMed ID: 177884
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell-mediated antitumor immune reactions under syngeneic conditions.
    Leclerc JC; Senik A; Gomard E; Plata F; Levy JP
    Transplant Proc; 1973 Dec; 5(4):1431-4. PubMed ID: 4359721
    [No Abstract]   [Full Text] [Related]  

  • 17. Examination of general and tumor-specific cell-mediated immune responses in mice bearing progressively growing plasmacytomas.
    Padarathsingh ML; McCoy JL; Dean JH; Lewis DD; Northing JW; Law LW
    J Natl Cancer Inst; 1977 Jun; 58(6):1701-7. PubMed ID: 301196
    [No Abstract]   [Full Text] [Related]  

  • 18. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens.
    Fujiwara H; Hamaoka T; Teshima K; Aoki H; Kitagawa M
    Immunology; 1976 Aug; 31(2):239-48. PubMed ID: 1085283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro induction and expression of T-cell immunity to tumor-associated antigens.
    Burton RC; Chism SE; Warner NL
    Contemp Top Immunobiol; 1978; 8():69-106. PubMed ID: 357081
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of H-2 antigens in the cytolysis of Oncornavirus induced tumour cells by syngeneic T lymphocytes [proceedings].
    Gomard E; Duprez V; Henin Y; Levy JP
    Folia Biol (Praha); 1976; 22(6):387-8. PubMed ID: 1087248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.